Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 17;25(3):40.
doi: 10.1208/s12249-024-02753-6.

Liposomal Formulation Reduces Transport and Cell Uptake of Colistin in Human Lung Epithelial Calu-3 Cell and 3D Human Lung Primary Tissue Models

Yijing Huang  1 , Shihui Yu  2 , Maizbha Uddin Ahmed  1 , Qi Tony Zhou  3
Affiliations

Liposomal Formulation Reduces Transport and Cell Uptake of Colistin in Human Lung Epithelial Calu-3 Cell and 3D Human Lung Primary Tissue Models

Yijing Huang et al. AAPS PharmSciTech. .

Abstract

Respiratory tract infections caused by multi-drug-resistant (MDR) bacteria have been a severe risk to human health. Colistin is often used to treat the MDR Gram-negative bacterial infections as a last-line therapy. Inhaled colistin can achieve a high concentration in the lung but none of aerosolized colistin products has been approved in the USA. Liposome has been reported as an advantageous formulation strategy for antibiotics due to its controlled release profile and biocompatibility. We have developed colistin liposomal formulations in our previous study. In the present study, the cellular uptake and transport of colistin in colistin liposomes were examined in two human lung epithelium in vitro models, Calu-3 monolayer and EpiAirway 3D tissue models. In both models, cellular uptake (p < 0.05) and cellular transport (p < 0.01) of colistin were significantly reduced by the colistin liposome compared to the colistin solution. Our findings indicate that inhaled colistin liposomes could be a promising treatment for extracellular bacterial lung infections caused by MDR Pseudomonas aeruginosa (P. aeruginosa).

Keywords: 3D human lung epithelial tissue model; Calu-3 cell; colistin; liposome; pulmonary delivery.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
In vitro colistin release profile of the liposomal formulation in HBSS at 37°C (mean ± SD, n = 3).
Figure 2.
Figure 2.
TEER value before and after the transport study (mean ± SD, n = 3). A) TEER value of Calu-3. B) TEER value of EpiAirway 3D tissue.
Figure 3.
Figure 3.
Colistin (col) uptake and transport in Calu-3 monolayer or EpiAirway 3D tissue model (mean ± SD, n = 3, * p<0.05, ** p<0.01, assessed by Unpaired t test using GraphPad Prism Version 9.0). A) Cellular uptake in Calu-3 monolayer. B) Cellular uptake in the EpiAirway 3D tissues. C) Remaining drug in apical chamber of Calu-3 monolayer. D) Remaining drug in the apical chamber of EpiAirway 3D tissue.
See this image and copyright information in PMC

References

    1. Moradali MF, Ghods S, Rehm BHA. Pseudomonas aeruginosa Lifestyle: A Paradigm for Adaptation, Survival, and Persistence. Frontiers in Cellular and Infection Microbiology. 2017;7. - PMC - PubMed
    1. Jurado-Martín I, Sainz-Mejías M, McClean S. Pseudomonas aeruginosa: An Audacious Pathogen with an Adaptable Arsenal of Virulence Factors. Int J Mol Sci. 2021;22(6). - PMC - PubMed
    1. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. The Lancet Infectious Diseases. 2006;6(9):589–601. - PubMed
    1. Grégoire N, Aranzana-Climent V, Magréault S, Marchand S, Couet W. Clinical Pharmacokinetics and Pharmacodynamics of Colistin. Clinical Pharmacokinetics. 2017;56(12):1441–60. - PubMed
    1. Beringer P The clinical use of colistin in patients with cystic fibrosis. Current Opinion in Pulmonary Medicine. 2001;7(6):434–40. - PubMed

LinkOut - more resources